Nancy Valente MD

Nancy Valente, M.D. is VP, Global Product Development Oncology and Head of Hematology Development at Genentech where she leads the clinical development of hematology medicines. A board certified hematologist and medical oncologist, she is focused on continuing to improve outcomes for people with diseases of the blood, including cancers and hemophilia. She was recognized by FiercePharma, as a Fierce Women in BioPhama in 2016.
Dr. Valente, who has more than 16 years of industry experience, joined Genentech in 2003. She is responsible for clinical development strategy for an extensive hematology portfolio, with medicines that span diverse mechanisms such as antibodies, antibody drug conjugates, apoptosis, immune therapy, and signaling. She oversees a team of 60 medical directors and clinical scientists located at three global sites in California, England and Switzerland.
During her time at Genentech, she has overseen the development programs for Rituxan, Gazyva, the first medicine with Breakthrough Designation to be approved by the FDA, and more recently Venclexta, a first-in-class pro apoptotic therapy. Previously, Dr. Valente held positions at Coulter Pharmaceutical and Anosys, Inc., leading the Phase I/III development of biologic therapeutics (antibodies and vaccines) for solid tumors and hematological malignancies.